Perspective of first line immune therapy of non-small-cell lung cancer
In this MEDtalk Ahmet Sezer, MD, professor, Department of Medical Oncology, Başkent University, Adana, Turkey, gives his perspective on treatment of non-small cell Lung cancer with immune therapy as first line treatment. He also gives his answer on how oncologists can choose wisely and how he would explain the survival benefit in the cemiplimab arm according to EMPOWER Lung 1 study.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.